Oral AZD5438 is a clinically translatable otoprotectant against cisplatin-induced hearing loss
Cisplatin-based chemotherapy causes hearing loss in 40–60 % of all patients, yet effective preventative options remain limited. Building on prior animal studies, we demonstrate that oral administration of AZD5438, a potent and selective CDK2 inhibitor, provides dose-dependent protection against hear...
Gespeichert in:
| Hauptverfasser: | , , , , |
|---|---|
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
Elsevier
2026-01-01
|
| Schriftenreihe: | Neoplasia: An International Journal for Oncology Research |
| Schlagworte: | |
| Online-Zugang: | http://www.sciencedirect.com/science/article/pii/S1476558625001307 |
| Tags: |
Keine Tags, Fügen Sie das erste Tag hinzu!
|